Scherlinger, Marc http://orcid.org/0000-0002-9453-5895
Richez, Christophe http://orcid.org/0000-0002-3029-8739
Tsokos, George C. http://orcid.org/0000-0001-9589-2360
Boilard, Eric http://orcid.org/0000-0001-6319-6432
Blanco, Patrick
Article History
Accepted: 15 December 2022
First Online: 27 January 2023
Change Date: 21 March 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41577-023-00869-7
Competing interests
: C.R. has received consulting or speaker fees from AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Biogen, Eli Lilly, GlaxoSmithKline, Janssen Novartis and Pfizer and grants from Biogen, Eli Lilly and Nordic Pharma, all unrelated to this work. M.S. has received consulting fees from Sandoz, Amgen and Nordic Pharma, all unrelated to this work. The other authors report no competing interests.
Free to read: This content has been made available to all.